A biopsy is a medical test commonly performed by a surgeon, interventional radiologist, or an interventional cardiologist involving extraction of sample cells or tissues for examination to determine the presence or extent of a disease. The tissue is generally examined under a microscope by a pathologist, and can also be analyzed chemically. When an entire lump or suspicious area is removed, the procedure is called an excisional biopsy. An incisional biopsy or core biopsy samples a portion of the abnormal tissue without attempting to remove the entire lesion or tumor. When a sample of tissue or fluid is removed with a needle in such a way that cells are removed without preserving the histological architecture of the tissue cells, the procedure is called a needle aspiration biopsy. Biopsies are most commonly performed for insight into possible cancerous and inflammatory conditions.
|ICD-10-PCS||0?D???X (without force),|
0?B???X (with force)
|OPS-301 code||1-40...1-49 (without incision)|
1-50...1-58 (with incision)
When cancer is suspected, a variety of biopsy techniques can be applied. An excisional biopsy is an attempt to remove an entire lesion. When the specimen is evaluated, in addition to diagnosis, the amount of uninvolved tissue around the lesion, the surgical margin of the specimen is examined to see if the disease has spread beyond the area biopsied. "Clear margins" or "negative margins" means that no disease was found at the edges of the biopsy specimen. "Positive margins" means that disease was found, and a wider excision may be needed, depending on the diagnosis.
When intact removal is not indicated for a variety of reasons, a wedge of tissue may be taken in an incisional biopsy. In some cases, a sample can be collected by devices that "bite" a sample. A variety of sizes of needle can collect tissue in the lumen (core biopsy). Smaller diameter needles collect cells and cell clusters, fine needle aspiration biopsy.
Pathologic examination of a biopsy can determine whether a lesion is benign or malignant, and can help differentiate between different types of cancer. In contrast to a biopsy that merely samples a lesion, a larger excisional specimen called a resection may come to a pathologist, typically from a surgeon attempting to eradicate a known lesion from a patient. For example, a pathologist would examine a mastectomy specimen, even if a previous nonexcisional breast biopsy had already established the diagnosis of breast cancer. Examination of the full mastectomy specimen would confirm the exact nature of the cancer (subclassification of tumor and histologic "grading") and reveal the extent of its spread (pathologic "staging").
There are two types of liquid biopsy (which is not really a biopsy as they are blood tests that do not require a biopsy of tissue): circulating tumor cell assays or cell-free circulating tumor DNA tests. These methods provide a non-invasive alternative to repeat invasive biopsies to monitor cancer treatment, test available drugs against the circulating tumor cells, evaluate the mutations in cancer and plan individualized treatments. In addition, because cancer is a heterogeneous genetic disease, and excisional biopsies provide only a snapshot in time of some of the rapid, dynamic genetic changes occurring in tumors, liquid biopsies provide some advantages over tissue biopsy-based genomic testing. In addition, excisional biopsies are invasive, can’t be used repeatedly, and are ineffective in understanding the dynamics of tumor progression and metastasis. By detecting, quantifying and characterisation of vital circulating tumor cells or genomic alterations in CTCs and cell-free DNA in blood, liquid biopsy can provide real-time information on the stage of tumor progression, treatment effectiveness, and cancer metastasis risk. This technological development could make it possible to diagnose and manage cancer from repeated blood tests rather than from a traditional biopsy.
Circulating tumor cell tests are already available but not covered by insurance yet at maintrac and under development by many pharmaceutical companies. Those tests analyze circulating tumor cells (CTCs) Analysis of individual CTCs demonstrated a high level of heterogeneity seen at the single cell level for both protein expression and protein localization and the CTCs reflected both the primary biopsy and the changes seen in the metastatic sites.
Analysis of cell-free circulating tumor DNA (cfDNA) has an advantage over circulating tumor cells assays in that there is approximately 100 times more cell-free DNA than there is DNA in circulating tumor cells. These tests analyze fragments of tumor-cell DNA that are continuously shed by tumors into the bloodstream. Companies offering cfDNA next generation sequencing testing include Personal Genome Diagnostics and Guardant Health. These tests are moving into widespread use when a tissue biopsy has insufficient material for DNA testing or when it is not safe to do an invasive biopsy procedure, according to a recent report of results on over 15,000 advanced cancer patients sequenced with the Guardant Health test.
A 2014 study of the blood of 846 patients with 15 different types of cancer in 24 institutions was able to detect the presence of cancer DNA in the body. They found tumor DNA in the blood of more than 80 percent of patients with metastatic cancers and about 47 percent of those with localized tumors. The test does not indicate the tumor site(s) or other information about the tumor. The test did not produce false positives.
Such tests may also be useful to assess whether malignant cells remain in patients whose tumors have been surgically removed. Up to 30 percent are expected to relapse because some tumor cells remain. Initial studies identified about half the patients who later relapsed, again without false positives.
Another potential use is to track the specific DNA mutations driving a tumor. Many new cancer medications block specific molecular processes. Such tests could allow easier targeting of therapy to tumor.
For easily detected and accessed sites, any suspicious lesions may be assessed. Originally, this was skin or superficial masses. X-ray, then later CT, MRI, and ultrasound along with endoscopy extended the range.
A biopsy of the temporal arteries is often performed for suspected vasculitis. In inflammatory bowel disease (Crohn's disease and ulcerative colitis), frequent biopsies are taken to assess the activity of disease and to assess changes that precede malignancy.
- Kidney disease: Biopsy and fluorescence microscopy are key in the diagnosis of alterations of renal function. The immunofluorescence plays vital role in the diagnosis of Crescentic glomerulonephritis.
- Infectious disease: Lymph node enlargement may be due to a variety of infectious or autoimmune diseases.
- Metabolic disease: Some conditions affect the whole body, but certain sites are selectively biopsied because they are easily accessed. Amyloidosis is a condition where degraded proteins accumulate in body tissues. In order to make the diagnosis, the gingival.
- Transplantation: Biopsies of transplanted organs are performed in order to determine that they are not being rejected or that the disease that necessitated transplant has not recurred.
- Fertility: A testicular biopsy is used for evaluating the fertility of men and find out the cause of a possible infertility, e.g. when sperm quality is low, but hormone levels still are within normal ranges.
|Bone||A bone biopsy is a procedure in which bone samples are removed to find out if cancer or infection or other abnormal cells are present. A bone biopsy involves the outer layers of bone, unlike a bone marrow biopsy, which involves the innermost part of the bone. Bone biopsy should as rule be done after all necessary imagings performed. Jamshidi needle has replaced the open-biopsy and fine-needle aspiration|
|Bone marrow||Since blood cells form in the bone marrow, a bone-marrow biopsy is employed in the diagnosis of abnormalities of blood cells when the diagnosis cannot be made from the peripheral blood alone. In malignancies of blood cells (leukemia and lymphoma) a bone-marrow biopsy is used in staging the disease. The procedure involves taking a core of trabecular bone using a trephine, and then aspirating material.|
|Breast||Breast biopsy is often performed to assess or diagnose breast cancer, and can be performed by various methods such as fine needle aspirate (FNA), core needle biopsy (CNB), or surgical removal.|
|Gastrointestinal tract||Flexible endoscopy enables access to the upper and lower gastrointestinal tract, such that biopsy of the esophagus, stomach and duodenum via the mouth and the rectum, colon and terminal ileum are commonplace. A variety of biopsy instruments, such as the bioptome, may be introduced through the endoscope and the visualized site biopsied. Until recently, the majority of the small intestine could not be visualized for biopsy. The double-balloon “push-pull” technique allows visualization and biopsy of the entire gastrointestinal tract.|
|Lung||Biopsies of the lung can be performed in a variety of ways depending on the location.|
|Liver||In hepatitis, most biopsies are not used for diagnosis, which generally occurs by other means. Rather, it is used to determine response to therapy which can be assessed by reduction of inflammation and progression of disease by the degree of fibrosis or, ultimately, cirrhosis.|
|Prostate||Forms of prostate biopsy include transrectal biopsy, transperineal biopsy and transurethral biopsy|
|Nervous system||Forms include brain biopsy, nerve biopsy, and meningeal biopsy|
|Urogenital system||Forms include renal biopsy, endometrial biopsy and cervical conization|
|Other||Other sites include lymph node biopsy, muscle biopsy, and skin biopsy|
Analysis of biopsied material
After the biopsy is performed, the sample of tissue that was removed from the patient is sent to the pathology laboratory. A pathologist specializes in diagnosing diseases (such as cancer) by examining tissue under a microscope. When the laboratory (see Histology) receives the biopsy sample, the tissue is processed and an extremely thin slice of tissue is removed from the sample and attached to a glass slide. Any remaining tissue is saved for use in later studies, if required.
The slide with the tissue attached is treated with dyes that stain the tissue, which allows the individual cells in the tissue to be seen more clearly. The slide is then given to the pathologist, who examines the tissue under a microscope, looking for any abnormal findings. The pathologist then prepares a report that lists any abnormal or important findings from the biopsy. This report is sent to the physician who originally performed the biopsy on the patient.
- Anderson JB, Webb AJ (1987). "Fine-needle aspiration biopsy and the diagnosis of thyroid cancer". The British Journal of Surgery. 74 (4): 292–296. doi:10.1002/bjs.1800740422. PMID 3580805.
- "biopsy". Online Etymology Dictionary.
- Zerbino DD (1994). "Biopsy: Its history, current and future outlook". Likars'ka Sprava / Ministerstvo Okhorony Zdorov'ia Ukrainy (3–4): 1–9. PMID 7975522.
- Sausville, Edward A. and Longo, Dan L. "Principles of Cancer Treatment: Surgery, Chemotherapy, and Biologic Therapy", Harrison's Principles of Internal Medicine, 16th Ed. Kaspar, Dennis L. et al., eds. p.446 (2005).
- Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall, Wallis M, Bentley D, Caldas C, Rosenfeld N (2013). "Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer". The New England Journal of Medicine. 368 (13): 1199–1209. doi:10.1056/NEJMoa1213261. PMID 23484797.CS1 maint: uses authors parameter (link)
- Pachmann, Katharina; Camara, Oumar; Kohlhase, Annika; Rabenstein, Carola; Kroll, Torsten; Runnebaum, Ingo B.; Hoeffken, Klaus (2010-08-08). "Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy". Journal of Cancer Research and Clinical Oncology. 137 (5): 821–828. doi:10.1007/s00432-010-0942-4. ISSN 0171-5216. PMC 3074080. PMID 20694797.
- Pachmann, K.; Stein, E.; Spitz, G.; Schill, E.; Pachmann, U. (2009-12-15). "Chemosensitivity Testing of Circulating Epithelial Cells (CETC) in Breast Cancer Patients and Correlation to Clinical Outcome". Poster Session Abstracts. American Association for Cancer Research: 2044. doi:10.1158/0008-5472.sabcs-09-2044.
- Oxnard GR, Paweletz CP, Sholl LM (October 7, 2016). "Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer". JAMA Oncology. 3 (6): 740–741. doi:10.1001/jamaoncol.2016.2835. PMID 27541382.CS1 maint: uses authors parameter (link)
- Marrinucci D, Bethel K, Luttgen M, Bruce RH, Nieva J, Kuhn P (Sep 2009). "Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type". Archives of Pathology & Laboratory Medicine. 133 (9): 1468–71. doi:10.1043/1543-2165-133.9.1468 (inactive 2019-08-20). PMC 4422331. PMID 19722757.
- Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, Rio Frio T, Pierron G, Callens C, Bieche I, Saliou A, Madic J, Rouleau E, Bidard FC, Lantz O, Stern MH, Le Tourneau C, Pierga JY (Apr 2015). "Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types". Molecular Oncology. 9 (4): 783–90. doi:10.1016/j.molonc.2014.12.003. PMC 5528781. PMID 25579085.CS1 maint: uses authors parameter (link)
- Nieva JJ, Kuhn P (Aug 8, 2012). "Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their disease". Future Oncology. 8 (8): 989–998. doi:10.2217/fon.12.91. PMC 3658625. PMID 22894671.
- Nieva J, Wendel M, Luttgen MS, Marrinucci D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, Bethel K, Kuhn P (Feb 2012). "High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis". Physical Biology. 9 (1): 016004. Bibcode:2012PhBio...9a6004N. doi:10.1088/1478-3975/9/1/016004. PMC 3388002. PMID 22306961.
- Hekimian K, Meisezahl S, Trompelt K, Rabenstein C, Pachmann K (2012). "Epithelial Cell Dissemination and Readhesion: Analysis of Factors Contributing to Metastasis Formation in Breast Cancer". ISRN Oncology. 2012: 601810. doi:10.5402/2012/601810. PMC 3317055. PMID 22530147.
- Rolle A, Günzel R, Pachmann U, Willen B, Höffken K, Pachmann K (2005). "Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R) is a predictor for relapse: A preliminary report". World J Surg Oncol. 3 (1): 18. doi:10.1186/1477-7819-3-18. PMC 1087511. PMID 15801980.
- Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A (Aug 2013). "Liquid biopsy: monitoring cancer-genetics in the blood". Nature Reviews Clinical Oncology. 10 (8): 472–484. doi:10.1038/nrclinonc.2013.110. PMID 23836314.
- Carl, S; Camara, O; Plaschke-Schluetter, A; Kroll, T; Pachmann, K. (2010-12-15). "Abstract P3-10-37: Molecular Analysis of Single Circulating Tumor Cells for Characterization of the Targets of Systemic Breast Cancer Therapy as Chance to Individualize Therapy". Poster Session Abstracts. American Association for Cancer Research: P3–10–37. doi:10.1158/0008-5472.sabcs10-p3-10-37.
- Jenks, Susan (Sep 2016). "Tracking Tumor Resistance: The Early Promise of "Liquid" Cancer Tests". Journal of the National Cancer Institute. 108 (9): djw220. doi:10.1093/jnci/djw220. PMID 27628661. Retrieved October 7, 2016.
- Regalado, Antonio (August 11, 2014). "Spotting Cancer in a Vial of Blood". MIT Technology Review. Retrieved 2016-04-23.
- Pachmann, Katharina; Dengler, Robert; Lobodasch, Kurt; Fröhlich, Frank; Kroll, Torsten; Rengsberger, Matthias; Schubert, Rene; Pachmann, Ulrich (2007-07-05). "An increase in cell number at completion of therapy may develop as an indicator of early relapse". Journal of Cancer Research and Clinical Oncology. 134 (1): 59–65. doi:10.1007/s00432-007-0248-3. ISSN 0171-5216. PMID 17611779.
- Pachmann, Katharina; Camara, Oumar; Kavallaris, Andreas; Krauspe, Sabine; Malarski, Nele; Gajda, Mieczyslaw; Kroll, Torsten; Jörke, Cornelia; Hammer, Ulrike (2008-03-10). "Monitoring the Response of Circulating Epithelial Tumor Cells to Adjuvant Chemotherapy in Breast Cancer Allows Detection of Patients at Risk of Early Relapse". Journal of Clinical Oncology. 26 (8): 1208–1215. doi:10.1200/jco.2007.13.6523. ISSN 0732-183X. PMID 18323545.
- Friedman, S. and Blumberg, R.S. "Inflammatory Bowel Disease", Harrison's Principles of Internal Medicine, 16th Ed. Kaspar, Dennis L. et al., eds. pp.1176-1789, 2005.
- Mens health - Testicular Biopsy
- Niederhuber, John E.; Armitage, James O.; Doroshow, James H.; Kastan, Michael B.; Tepper, Joel E. (2013-09-12). Abeloff's clinical oncology (Fifth ed.). Philadelphia, Pennsylvania. ISBN 9781455728817. OCLC 857585932.
- Baim, Donald S. (2006). Grossman's Cardiac Catheterization, Angiography, and Intervention. Lippincott Williams & Wilkins. ISBN 9780781755672.
- Saibeni S, Rondonotti E, Iozzelli A, Spina L, Tontini GE, Cavallaro F, Ciscato C, de Franchis R, Sardanelli F, Vecchi M (2007). "Imaging of the small bowel in Crohn's disease: a review of old and new techniques". World J. Gastroenterol. 13 (24): 3279–87. doi:10.3748/wjg.v13.i24.3279. PMC 4172707. PMID 17659666.
- Iglesias-Garcia J, Dominguez-Munoz E, Lozano-Leon A, Abdulkader I, Larino-Noia J, Antunez J, Forteza J (2007). "Impact of endoscopic ultrasound-guided fine needle biopsy for diagnosis of pancreatic masses". World J. Gastroenterol. 13 (2): 289–93. doi:10.3748/wjg.v13.i2.289. PMC 4065960. PMID 17226911.
- Mybiopsyinfo.com - What is a biopsy? How is a biopsy examination performed? This website gives you answers to these and many other questions.
- MyBiopsy.org - Links to a video. Information about biopsy results for patients. This site is created by pathologists, the physicians who diagnose cancer and other diseases by looking at biopsies under a microscope.
- RadiologyInfo - The radiology information resource for patients: Biopsy